Immix Biopharma, Inc. (IMMX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−19.0x

Market Cap

$995.11M

MomentumView details →

1D Return

+0.58%

YTD Return

+164.15%

RSI (14)

66.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−19.0x

Market Cap

$995.11M

RSI (14)

66.6

MomentumView details →

1D Return

+0.58%

YTD Return

+164.15%

SummaryUpdated Jun 1, 2026

Immix Biopharma, Inc. (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Los Angeles, California. The company went public in December 2021 and focuses on developing tissue-specific therapeutics for oncology and inflammatory diseases. Immix operates primarily in the United States and Australia, with its lead programs currently in various phases of clinical trials targeting cancer and inflammatory bowel diseases.

Ask drillr about Immix Biopharma, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−17.44%

ROA (TTM)

−16.69%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−12.82%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−17.11%

EBITDA YoY

−72.72%

EarningsView details →

EPS (Actual)

−$0.18

EPS Surprise

−5.88%

Beats (12Q)

3/12

Next Q EPS Est

−$0.19

Avg Surprise (4Q)

−15.54%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

25.13x

Quick Ratio

25.13x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−39.92M

Op. CF (TTM)

−38.50M

Next earningsNov 6, 2026 →

Latest newsMore news →

Immix Biopharma's stock reached a new 52-week high of $13.80 during mid-day trading on Tuesday, with the last trade at $13.61 and volume of 1,414,936 shares.11d ago

The Portnoy Law Firm initiated an investigation into Immix Biopharma for possible securities fraud and may file a class action on behalf of investors.45d ago

Similar companies

Lexicon Pharmaceuticals, Inc.LXRX Ventyx Biosciences, Inc.VTYX Geron CorporationGERN Candel Therapeutics, Inc.CADL Ardelyx, Inc.ARDX Arbutus Biopharma CorporationABUS Find similar companies →

Latest newsMore news →

Immix Biopharma's stock reached a new 52-week high of $13.80 during mid-day trading on Tuesday, with the last trade at $13.61 and volume of 1,414,936 shares.11d ago The Portnoy Law Firm initiated an investigation into Immix Biopharma for possible securities fraud and may file a class action on behalf of investors.45d ago